Two subsidiaries of Wockhardt Ltd. have settled an ongoing commercial lawsuit in the London High Court with Teva Pharmaceuticals USA Inc. and its affiliate Cephalon Inc regarding a supply contract.
The dispute was around the price charged by CP Pharmaceuticals Ltd., a subsidiary of Wockhardt's U.K. unit, from Cephalon for a drug named Trisenox.
Under the terms of settlement, CP Pharmaceuticals has waived its claim for outstanding trade receivables worth £20 million, and agreed to pay £23 million to Teva and Cephalon, according to a stock exchange filing by Wockhardt.
The litigation, which started in September 2015, is now closed and all claims are dismissed, the filing added.
Shares of Wockhardt Ltd. closed 3.4 percent lower ahead of the announcement, compared to the benchmark BSE Sensex which remained largely flat.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
